 |
|
|
| |
Single Dose Safety, Tolerability and Pharmacokinetics of AB-423 in Healthy Volunteers from the ongoing Single and Multiple Ascending Dose Study AB-423-001
|
| |
| |
Reported by Jules Levin
Reported by Jules Levin
AASLD: The Liver Meeting® 2017, October 20-24, 2017, Washington, DC
Timothy Eley1, Sofia Caamano1, Jill Denning1, Karen Sims1, Richard Larouche2, William Symonds1, Patricia Mendez1
1Arbutus Biopharma Corporation, Burnaby, BC, Canada. 2.InVentiv Health, Quebec, QC, Canada
|
| |
|
|
|
|
|
